15:09:19 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Idogen är verksamma inom bioteknik. Bolagets affärsinriktning är att utveckla vaccinkandidater för behandling av sjukdomar som negativt påverkar immunförsvaret. Vaccinen avses att användas i de fall där det uppkommit autoimmuna sjukdomar och efter organavstötning, särskilt vid de fall där de bildats antikroppar mot intagningen av patientens ordinarie läkemedel. Bolaget grundades under 2008 och har sitt huvudkontor i Lund.

Kalender

2023-02-08 Bokslutskommuniké 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-05 Ordinarie utdelning IDOGEN 0.00 SEK
2022-05-04 Årsstämma 2022
2022-05-04 Kvartalsrapport 2022-Q1
2022-01-20 Extra Bolagsstämma 2022
2022-01-19 Bokslutskommuniké 2021
2021-10-26 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-12 Ordinarie utdelning IDOGEN 0.00 SEK
2021-05-11 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-11-04 Extra Bolagsstämma 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-27 Split IDOGEN 10:1
2020-05-13 Ordinarie utdelning IDOGEN 0.00 SEK
2020-05-12 Kvartalsrapport 2020-Q1
2020-05-12 Årsstämma 2020
2020-01-29 Bokslutskommuniké 2019
2019-10-22 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-06-26 Ordinarie utdelning IDOGEN 0.00 SEK
2019-06-25 Årsstämma 2019
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-06 Bokslutskommuniké 2018
2018-10-23 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-04-25 Ordinarie utdelning IDOGEN 0.00 SEK
2018-04-24 Kvartalsrapport 2018-Q1
2018-04-24 Årsstämma 2018
2018-02-06 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-08-30 Kvartalsrapport 2017-Q2
2017-05-18 Ordinarie utdelning IDOGEN 0.00 SEK
2017-05-17 Årsstämma 2017
2017-04-24 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-11-11 Kvartalsrapport 2016-Q3
2016-08-26 Kvartalsrapport 2016-Q2
2016-04-26 Årsstämma 2016
2016-04-26 Kvartalsrapport 2016-Q1
2016-02-18 Ordinarie utdelning IDOGEN 0.00 SEK
2016-02-17 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-27 Kvartalsrapport 2015-Q2
2020-08-25 08:30:00

January 1 - June 30, 2020
Second quarter (April-June 2020)

  • Other operating income amounted to KSEK 2,782 (1,141)
  • Operating loss was KSEK -7,292 (-11,307 of which impairment loss on patents amounted to KSEK -4,573) KSEK
  • Loss for the period totalled -7,976 (-11,213) KSEK
  • Cash flow from operating activities was KSEK -9,003 (-6,531)
  • Loss per share was SEK -0.87 (-2.31)
Period (January-June 2020)
  • Other operating income amounted to KSEK 4,195 (1,994)
  • Operating loss was KSEK -13,952 (-18,069)
  • Loss for the period totalled KSEK -14,197 (-17,856)
  • Cash flow from operating activities was KSEK -10,788 (-18,562)
  • Loss per share was SEK -2.03 (-3.68)
Significant events in the second quarter
  • In June, Idogen was approved for listing on Nasdaq First North Growth Market.
  • From June 4, Idogen's shares are traded on Nasdaq First North, which was noted on Time Square in New York. 
  • Idogen's collaboration parner established a GMP-certified process for large-scale production of the company's cell therapy product.
  • The ongoing Corona pandemic has so far had some impact on the company's operations. During the pandemic, Radboud University Medical Center has worked at reduced capacity. In collaboration with Radboud, Idogen continuously monitors the possible impact on our development plans that could arise if Radboud is not able to return to its normal level of activity in the near future.
Significant events in the second quarter
  • At the end of January, Crown Princess Victoria and Prince Daniel visited Idogen to learn more about the company's tolerogenic cell therapy.
  • A rights issue underwritten to 88% was completed in March, and generated net proceeds of MSEK 20.6 for Idogen.
  • In March, disbursements from the EU's Horizon 2020 programme resumed and KEUR 550 was paid out.
Significant events after the end of the period
  • In july, Åsa Schiött was appointed new Chief Scientific Officer (CSO) and Vicky Venizelos Chief Regulatory Officer (CRO).
  • No other significant events occurred after the end of the period that affected the results or financial position.
If you have any questions, please contact:
Anders Karlsson, Chief Executive Officer
Phone: +46 (0) 709 18 00 10
E-mail: anders.karlsson@idogen.com
Certified Adviser
Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm
Phone: +46 (0)8-463 80 00
E-mail: certifiedadviser@penser.se.
Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissues. The company's most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralising antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favourable safety profile and long-lasting effect. The potential for a short-term treatment to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.